NanOlogy enrols first patient in phase 2 trial of NanoPac for intratumoral treatment of prostate cancer

This article was originally published here

The single arm trial is evaluating up to 3 monthly injections of the investigational drug in patients scheduled for prostatectomy approximately 90 days after the first injection. Patients

The post NanOlogy enrols first patient in phase 2 trial of NanoPac for intratumoral treatment of prostate cancer appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply